Business
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
INOVIO (NASDAQ: INO), and Akeso, Inc. (9926.HK) ("Akeso") today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO's DNA immunotherapy candidate, in combination with cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute and co
About this update from Akeso, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer","length":224,"tagName":"p"}]},{"val":[{"type":"text","content":"Novel combination therapy will be studied as part of the Phase 2 adaptive platform trial known as the INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT), sponsored by the Dana-Farber Cancer Institute ","length":229,"tagName":"p"}]},{"val":[{"type":"text","content":"Study builds on the previously reported positive Phase 2 results involving INO-5401 in GBM, adding a novel, first-in-class PD-1/CTLA-4 bi-specific immunotherapy, which potentially provides additional checkpoint inhibition through CTLA-4 binding","length":249,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":702,"olType":false},{"type":"text","content":"PLYMOUTH MEETING, Pa. and HONG KONG, March 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), and Akeso, Inc. (9926.HK) ("Akeso") today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO's DNA immunotherapy candidate, in combination with cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute and conducted with Mass General Brigham Cancer Care, Inc., which is designed to quickly and efficiently find new treatments for GBM. Dosing in the combination therapy trial is expected to begin in the second half of 2026.","length":800,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":129,"url":"https://media.zenfs.com/en/prnewswire.com/02f6eff2e3f0f811a2f544c30d57cb0d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Yd1bAc6HmDvRUbv9UGxnLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/02f6eff2e3f0f811a2f544c30d57cb0d","width":400,"height":12...